MedTrace Logo

An Open-labeled Phase II Study to Evaluate the Efficacy and Safety of GXNPC-1 in Patients with Chronic Stroke

NCT04088149 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-09-19

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy for subjects with chronic stroke after GXNPC-1 injection.

Conditions

  • Chronic Stroke

Interventions

DRUG

GXNPC1

Autologous ADSCs

Sponsors & Collaborators

  • Gwo Xi Stem Cell Applied Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Chiu Ts Lang, Director · Hualien Tzu Chi General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-06
Primary Completion
2023-08-15
Completion
2024-09-03

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04088149 on ClinicalTrials.gov